As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
6 Analysts have issued a Leap Therapeutics, Inc. forecast:
6 Analysts have issued a Leap Therapeutics, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -71 -71 |
20%
20%
|
EBIT (Operating Income) EBIT | -71 -71 |
20%
20%
|
Net Profit | -69 -69 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Doug Onsi |
Employees | 52 |
Founded | 2011 |
Website | www.leaptx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.